Moderna and Merck's personalized cancer vaccine fuels a new growth narrative
Moderna and Merck reported positive Phase 3 data for intismeran autogene, a personalized cancer vaccine, in combination with Keytruda for melanoma, showing longer cancer-free survival versus Keytruda alone. The readout prompted stock upgrades and higher price targets for both companies, highlighting the potential of a market-of-one approach despite uncertainties about market size and applicability to other cancers. The vaccine’s roughly six-week manufacturing window enables concurrent treatment with Keytruda, raising the prospect of a new growth driver if similar results extend to other solid tumors; however, success in one cancer type does not guarantee broader approvals.
